Label Changes for:
Vectibix (Panitumumab) Injection for Intravenous Infusion
August 2012
Changes have been made to the WARNINGS, PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2012
WARNINGS AND PRECAUTIONS
Dermatologic Toxicity
- Monitor patients who develop dermatologic toxicities while receiving Vectibix for the development of inflammatory or infectious sequelae…
